Novo Nordisk's long-acting insulin Tresiba is set to gain new hypoglycaemia prevention claims in Europe, giving it an advantage over Sanofi’s top-selling Lantus. Europe's CHMP committee has just ...
There are currently shortages of the Tresiba FlexTouch insulin pen which could affect people living with diabetes who take Tresiba insulin. Here’s what you need to know.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback